Tree Nut Allergy Market Size & Share Analysis - Growth Trends and Forecast (2026 - 2031)

Global Tree Nut Allergy Market Trends and Insights

Rising Pediatric Prevalence of IgE-Mediated Tree-Nut Allergy

A 2024 Turkish cohort reported that 60% of newly diagnosed tree-nut allergic children experienced multi-system reactions requiring epinephrine.^{[2]Turkish Journal of Pediatrics, “Multi-system Tree Nut Allergy Presentations in Turkish Children,” turkishjournalpediatrics.org} Additionally, a 2025 European registry identified hazelnut, walnut, and cashew as the cause of 73% of pediatric anaphylaxis cases across Germany, France, and Italy.^{[3]European Allergy Registry, “Pediatric Tree Nut Anaphylaxis in Europe,” eaaci.org} The POSEIDON Phase 3 trial demonstrated a 68.4% desensitization rate to 1,000 mg of peanut protein in children aged 1–4 years, highlighting the significance of early-life intervention.^{[4]Journal of Allergy and Clinical Immunology: Global, “Eliciting Doses Among Japanese Children,” jacionline.org} Furthermore, real-world data from France associated sublingual immunotherapy with a 38% reduction in asthma risk, reinforcing its preventive potential.

Accelerated Approvals of Disease-Modifying Immunotherapies (OIT, SLIT, EPIT)

In 2026, DBV Technologies submitted a Biologics License Application following positive VITESSE Phase 3 results, which demonstrated significant desensitization in children aged 4–7 years. In February 2024, Omalizumab became the first anti-IgE therapy approved for multiple food allergies, driving a shift in treatment guidelines toward the integration of biologics. Additionally, ALK-Abelló’s successful peanut-tablet Phase 2 results in April 2026 indicated further diversification in administration methods.

Expansion of Component-Resolved Diagnostics in Clinical Practice

Component-level assays now effectively differentiate high-risk seed-storage proteins, such as Ana o 3 in cashew and Jug r 1 in walnut, from pollen cross-reactive proteins, enabling tailored oral-food challenges. At the 2025 AAAAI symposium, Ana o 3 titers above 0.32 kUA/L were identified as predictive of cashew anaphylaxis. Research from Belgium demonstrated that adopting Component-Resolved Diagnostics (CRD) reduced unnecessary challenges by 34% and facilitated the re-introduction of tolerated nuts in 28% of cases.

Launch of Smart, Connected Epinephrine Autoinjectors with Adherence Analytics

Kaleo’s voice-guided Auvi-Q expanded its product line to include a 0.1 mg infant dose designed for toddlers weighing 7.5–15 kg. Data from 2025 indicated a 19% reduction in hospitalization rates within 24 hours of anaphylaxis when using these advanced devices compared to traditional options. Aquestive Therapeutics is re-submitting Anaphylm, a sublingual epinephrine film, after addressing regulatory feedback in January 2026. If approved, it could become the first needle-free emergency solution.

High Costs & Limited Reimbursement Hurdles for Biologic Therapies

Omalizumab, a leading biologic therapy, is priced at over USD 2,000 per month. U.S. payers enforce prior-authorization requirements, including the submission of serum-IgE documentation and prescriptions from allergists. Medicare Part D beneficiaries face coinsurance rates of 25-33%, resulting in monthly out-of-pocket expenses ranging from USD 500 to 700. By 2025, 14 state Medicaid plans are expected to mandate step therapy through oral immunotherapy before approving biologics, potentially restricting access for low-income families.

Safety Concerns & Adherence Issues with Extended Immunotherapy Protocols

A 2025 survey reported a 5% dropout rate from oral immunotherapy due to intolerable side effects, with 13% of patients requiring dose adjustments after severe reactions. Data also indicated that 71.8% of patients experienced adverse events, most of which were mild; however, concerns about anaphylaxis remain a key factor driving discontinuation. Additionally, social factors such as the inconvenience of daily dosing and gastrointestinal discomfort further exacerbate challenges in adherence to treatment protocols.

Segment Analysis

By Product Type: Disease-Modifying Therapies Challenge Acute-Care Dominance

Acute-care drugs, including epinephrine autoinjectors, antihistamines, and corticosteroids, accounted for 42.50% of 2025 revenue, highlighting their critical role in emergency management. The demand for epinephrine has been strengthened by the introduction of infant-dose products and affordable generics. However, disease-modifying agents, led by oral immunotherapy and omalizumab, are growing at an 8.88% CAGR, shifting the clinical focus from emergency interventions to preventive care. Guidelines emphasize that biologics are preventive in nature and should not replace epinephrine in acute situations.

By Tree-Nut Type: Cashew Expands Amid Dietary Shifts

Walnuts captured 28.55% of the 2025 segment revenue, reflecting their widespread use in baked goods and plant-based milks. Hazelnut oral immunotherapy achieved a high desensitization rate but provided minimal cross-protection to other nuts, underscoring the need for nut-specific treatment approaches. Rising cashew consumption in Asia is driving a 6.99% CAGR, with increasing demand for cashew-specific allergy treatments as exposure grows.

By End User: Specialty Clinics Lead Immunotherapy Growth

Hospital pharmacies accounted for 55.34% of 2025 sales, driven by the need for emergency equipment and trained personnel during supervised treatment phases. However, specialty allergy clinics are experiencing an 8.34% CAGR, driven by integrated care models that combine oral immunotherapy, biologics, diagnostics, and clinical trial enrollment. These clinics differentiate themselves through value-based care contracts and remote-monitoring tools that enhance treatment adherence.

By Age Group: Pediatric Cohort Anchors Market Expansion

Pediatric patients represented 60.43% of the projected demand for 2025 and are expected to grow at a compound annual growth rate (CAGR) of 7.56%. This growth is attributed to advancements in early diagnostics and increased caregiver willingness to invest in tolerance-inducing therapies. The observed efficacy in preschool-age children during the POSEIDON trial highlights the significance of initiating interventions before school entry. Furthermore, the anticipated Viaskin Peanut application for children aged 1 to 3 years reflects the regulatory focus on addressing the needs of the youngest patient segment.

Geography Analysis

In 2025, North America secured 39.67% of the geographic revenue, driven by the United States' rapid adoption of omalizumab following its FDA approval in February 2024. This growth was supported by the widespread availability of epinephrine auto-injectors through retail and specialty pharmacies and a well-established network of allergy clinics providing Oral Immunotherapy (OIT). In January 2025, the American Academy of Allergy, Asthma & Immunology issued consensus guidance on omalizumab, standardizing patient selection criteria and dosing regimens. Additionally, the 2024 AAAAI-EAACI PRACTALL update aligned oral food challenge protocols, reducing variability across centers and facilitating multi-site clinical trials. Europe, accounting for approximately 28% of the market in 2025, saw Germany, the United Kingdom, France, Italy, and Spain leading in OIT adoption. However, a regulatory gap emerged as the European Medicines Agency's Committee for The EAACI 2024 guidelines recommended omalizumab and OIT for peanut allergies but highlighted limited evidence for tree nuts, which slowed reimbursement and broader adoption.

Asia-Pacific, experiencing a 7.90% CAGR through 2031, is driven by dietary westernization, which has increased tree nut consumption and sensitization rates. A 2025 study documented that eliciting doses for walnut and cashew in Japanese children are now approaching Western thresholds, attributed to rising nut consumption over the past decade. Additionally, China's tree nut import volume grew significantly between 2015 and 2024. The Middle East and Africa, led by Gulf Cooperation Council countries and South Africa, along with South America, anchored by Brazil and Argentina, collectively represent approximately 10% of the market. Growth in these regions is constrained by a limited number of specialists, low awareness of immunotherapy, and high out-of-pocket costs for biologics and diagnostics. However, urbanization and rising incomes are expected to narrow these gaps over the forecast period.